[18F]FDG PET/CT 预测系统性硬化症相关间质性肺病患者的生存
前瞻性纳入45例系统性硬化症相关间质性肺病(SSc-ILD)患者行[18F]FDG PET/CT,中位随访44.8±26.1个月期间记录15例死亡(33%)。多因素Cox回归显示,肺SUVmin(HR 4.2,95%CI 1.3-13.4,P=0.017)和ILD-GAP指数(HR 3.9,95%CI 1.2-12.8,P=0.024)是总生存的独立预测因子;将[18F]FDG摄取与ILD-GAP评分数据结合构建改良ILD-GAP指数可改善死亡风险预测(P<0.002)。
要点
- 肺SUVmin(HR 4.2,95%CI 1.3-13.4)和ILD-GAP指数(HR 3.9,95%CI 1.2-12.8)是SSc-ILD总生存的独立预测因子。
- 高肺SUVmax(P=0.027)、高SUVmin(P=0.002)、低TBR(P=0.016)均与死亡率升高相关。
- [18F]FDG摄取与ILD-GAP评分结合构建的改良ILD-GAP指数可改善死亡预测(P<0.002)。
核心结论
- 正常表现肺的高背景[18F]FDG摄取可独立预测SSc-ILD患者的总生存,与ILD-GAP评分数据结合构建改良ILD-GAP指数时可能对患者进行风险分层。
- 高肺[18F]FDG摄取与SSc-ILD患者死亡率升高相关。
研究设计与样本
- 前瞻性纳入45例SSc-ILD患者(12例男性、33例女性;年龄58.9±9.9岁)行[18F]FDG PET/CT,为目前已知该类型最大队列。
- 所有患者接受临床评估,包括多学科团队评审、高分辨率CT评估和肺功能检查。
- 采用感兴趣区分析定量肺最大摄取(SUVmax)、未受累或背景肺最小摄取(SUVmin)及靶/本底比值(TBR=SUVmax/SUVmin)。
- 采用Kaplan-Meier分析评估与死亡率的关联,并以逐步前向Wald-Cox分析评估[18F]FDG PET/CT指标的独立性。
- 分析[18F]FDG PET/CT测量、肺功能检查与基于性别、年龄和肺生理的既定模型(ILD-GAP)预测死亡率之间的关联。
主要发现
- 45例SSc-ILD患者平均随访44.8±26.1个月,记录15例死亡(33%)。
- SUVmax均值±SD为3.2±1.1,SUVmin为0.5±0.3,TBR为6.8±2.6。
- 死亡率升高与高肺SUVmax(P=0.027)、高SUVmin(P=0.002)、低TBR(P=0.016)、低用力肺活量(P=0.021)、低一氧化碳弥散系数(P=0.021)、低转移因子(P=0.012)、高ILD-GAP评分(P=0.010)和高ILD-GAP指数(P=0.005)相关。
- 多因素Cox回归显示,肺SUVmin(HR 4.2,95%CI 1.3-13.4,P=0.017)和ILD-GAP指数(HR 3.9,95%CI 1.2-12.8,P=0.024)是总生存的独立预测因子。
- 将[18F]FDG摄取与ILD-GAP评分数据结合构建改良ILD-GAP指数可改善死亡预测能力(P<0.002)。
临床怎么用
- 原文结论指出,正常表现肺的高背景[18F]FDG摄取可独立预测SSc-ILD患者的总生存,并可能与ILD-GAP评分数据结合构建改良ILD-GAP指数以对患者进行风险分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There are few effective prognostic biomarkers in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). We investigated the potential of [18F]FDG PET/CT to predict mortality in this population. Methods: In total, 45 patients with SSc-ILD (12 men and 33 women; age, 58.9 ± 9.9 y) were prospectively recruited for [18F]FDG PET/CT, forming the largest cohort of this type to our knowledge. All patients underwent clinical assessment, including multidisciplinary team review, high-resolution CT evaluation, and pulmonary function tests. The maximum pulmonary uptake on [18F]FDG PET/CT (SUVmax), minimum pulmonary uptake in unaffected or background lung (SUVmin), and target-to-background ratio (TBR) (SUVmax/SUVmin) were quantified using region-of-interest analysis. Kaplan-Meier analysis identified associations with mortality. Associations between [18F]FDG PET/CT measurements, pulmonary function tests, and the established model based on sex, age, and lung physiology (known as ILD-GAP) to predict mortality were performed. Stepwise forward Wald-Cox analysis assessed the independence of significant [18F]FDG PET/CT measurements from the ILD-GAP index. Synergies between pulmonary [18F]FDG PET/CT measurements and ILD-GAP index for risk stratification in patients with SSc-ILD were investigated. Results: Forty-five patients with SSc-ILD were followed for a mean of 44.8 ± 26.1 mo, with 15 deaths (33%) recorded. The mean ± SD SUVmax was 3.2 ± 1.1, SUVmin was 0.5 ± 0.3, and TBR was 6.8 ± 2.6. Increased mortality was associated with high pulmonary SUVmax (P = 0.027), high SUVmin (P = 0.002), low TBR (P = 0.016), low forced vital capacity (P = 0.021), low carbon monoxide diffusion coefficient (P = 0.021), low transfer factor (P = 0.012), high ILD-GAP score (P = 0.010), and high ILD-GAP index (P = 0.005). Multivariate Cox regression analysis revealed that pulmonary SUVmin (hazard ratio, 4.2; 95% CI, 1.3-13.4; P = 0.017) and ILD-GAP index (hazard ratio, 3.9; 95% CI, 1.2-12.8; P = 0.024) were the only independent predictors of overall survival. Combining [18F]FDG uptake with ILD-GAP score data in a modified ILD-GAP index refined the ability to predict mortality (P < 0.002). Conclusion: High-background [18F]FDG uptake in normal-appearing lung independently predicts overall survival in SSc-ILD and may stratify patients' risk when combined with ILD-GAP score data in a modified ILD-GAP index. High pulmonary [18F]FDG uptake is associated with increased mortality in patients with SSc-ILD.
引用
- Lilburn DML, Garthwaite HS, Ganeshan B, et al. [18F]FDG PET/CT Predicts Patient Survival in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease. J Nucl Med. 2025. PMID: 40441891. doi:10.2967/jnumed.125.269497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。